Reference : Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed thera...
Scientific journals : Article
Human health sciences : Immunology & infectious disease
http://hdl.handle.net/2268/71237
Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006.
English
Vercauteren, Jurgen [Katholieke Universiteit Leuven - KUL > Rega Institute for Medical Research and University Hospitals > > >]
Derdelinckx, Inge [Katholieke Universiteit Leuven - KUL > Rega Institute for Medical Research and University Hospitals > > >]
Sasse, Andre [Scientific Institute of Public Health, Brussels, Belgium. > > > > > >]
Bogaert, Marleen [Universitair Ziekenhuis Gent - UZ > > > >]
Ceunen, Helga [Katholieke Universiteit Leuven - KUL > Rega Institute for Medical Research and University Hospitals > > >]
De Roo, Ann [> > > >]
De Wit, Stephane [> > > >]
Deforche, Koen [> > > >]
Echahidi, Fedoua [> > > >]
Fransen, Katrien [> > > >]
Goffard, Jean-Christophe [> > > >]
Goubau, Patrick [> > > >]
Goudeseune, Elodie [> > > >]
Yombi, Jean-Cyr [> > > >]
Lacor, Patrick [> > > >]
Liesnard, Corinne [> > > >]
Moutschen, Michel mailto [Université de Liège - ULg > Département des sciences cliniques > Immunopathologie - Transplantation >]
Piérard, Denis [Universitair Ziekenhuis Brussel > > > >]
Rens, Roeland [> > > >]
Schrooten, Yoeri [> > > >]
Vaira, Dolorès mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie biologique et immuno hématologie >]
van den Heuvel, Annelies [> > > >]
van der Gucht, Bea [> > > >]
van Ranst, Marc [> > > >]
van Wijngaerden, Eric [> > > >]
Vandercam, Bernard [> > > >]
Vekemans, Marc [> > > >]
Verhofstede, Chris [> > > >]
Clumeck, Nathan [> > > >]
Vandamme, Anne-Mieke [> > > >]
van Laethem, Kristel [> > > >]
2008
AIDS Research and Human Retroviruses
Mary Ann Liebert, Inc.
24
3
355-62
Yes (verified by ORBi)
International
0889-2229
1931-8405
Larchmont
NY
[en] Adult ; Aged ; Aged, 80 and over ; Anti-HIV Agents/pharmacology ; Belgium/epidemiology ; Drug Resistance, Viral/genetics ; Female ; Genotype ; HIV Infections/epidemiology/physiopathology/transmission/virology ; HIV Protease/genetics ; HIV Reverse Transcriptase/genetics ; HIV-1/drug effects/genetics/isolation & purification ; Humans ; Male ; Middle Aged ; Molecular Sequence Data ; Prospective Studies ; Questionnaires ; RNA, Viral/blood/genetics/isolation & purification ; Reverse Transcriptase Polymerase Chain Reaction ; Sequence Analysis, DNA
[en] This study is the first prospective study to assess the prevalence, epidemiology, and risk factors of HIV-1 drug resistance in newly diagnosed HIV-infected patients in Belgium. In January 2003 it was initiated as part of the pan-European SPREAD program, and continued thereafter for four inclusion rounds until December 2006. Epidemiological, clinical, and behavioral data were collected using a standardized questionnaire and genotypic resistance testing was done on a sample taken within 6 months of diagnosis. Two hundred and eighty-five patients were included. The overall prevalence of transmitted HIV-1 drug resistance in Belgium was 9.5% (27/285, 95% CI: 6.6-13.4). Being infected in Belgium, which largely coincided with harboring a subtype B virus, was found to be significantly associated with transmission of drug resistance. The relatively high rate of baseline resistance might jeopardize the success of first line treatment as more than 1 out of 10 (30/285, 10.5%) viruses did not score as fully susceptible to one of the recommended first-line regimens, i.e., zidovudine, lamivudine, and efavirenz. Our results support the implementation of genotypic resistance testing as a standard of care in all treatment-naive patients in Belgium.
http://hdl.handle.net/2268/71237
10.1089/aid.2007.0212

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
aid%2E2007%2E0212.pdfPublisher postprint79.68 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.